• 5 min read
• Published on 10 January 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
For years, the phrase ‘Made in America’ felt like a dusty slogan, a relic from a time before global supply chains became the gospel of corporate efficiency. Yet, in the world of pharmaceuticals, it’s making a rather spectacular comeback. And I think the reasons why are incredibly telling for anyone looking to understand where serious money is heading next. This isn’t about patriotism. It’s about pragmatism, profit, and a powerful lesson learned the hard way.
At the heart of this shift is a rather clever bit of horse trading from Washington. The government has effectively told Big Pharma that if they bring their manufacturing back to U.S. soil and offer better prices on drugs, they’ll get a nice break on tariffs for essential materials. It's a simple, elegant quid pro quo, and it seems to be working a treat. We’re not talking about minor tweaks here. Giants like Johnson & Johnson are committing billions to build and upgrade facilities. This isn’t just shuffling a few production lines around, it’s a fundamental rewiring of the industry’s physical footprint. These are long term, concrete-and-steel decisions, the kind that aren’t easily reversed when a new political wind blows.
Let’s be honest, the real catalyst for this was the global chaos of recent years. Do you remember the desperate scramble for basic medical supplies? It exposed a shocking vulnerability. The idea that life-saving medicines depended on supply chains stretching halfway across the planet suddenly looked less like shrewd economics and more like strategic lunacy. To me, this is the core of the story. Companies like Pfizer and Merck learned that while offshoring might look good on a spreadsheet in peacetime, it’s a terrifying liability in a crisis. They are now spending fortunes to have more control, to know that their most critical production lines are a truck-drive away, not an ocean voyage.
Now, this is where it gets particularly interesting from an investor's perspective. This manufacturing renaissance isn’t just enriching the household names. When you build a new factory, you don’t just hire factory workers. You need an entire ecosystem to support it. Think of the specialist contractors who build sterile environments, the suppliers of highly advanced laboratory equipment, and the logistics firms that can handle temperature-sensitive medicines. An entire secondary industry is flourishing in the shadow of this onshoring push. To my mind, this is where some of the most compelling opportunities could be found, as the U.S. Drug Manufacturing | Multi-Billion Investment Push creates a powerful ripple effect that touches dozens of specialist, and often overlooked, companies.
So, what should we take away from all this? When you see companies pouring billions into physical assets that will operate for decades, it signals a deep confidence in a long term trend. The political support for secure domestic supply chains appears solid, suggesting these incentives are here to stay. Of course, risks remain. Building anything in the United States is expensive, and finding enough skilled labour is a genuine challenge that could pressure profit margins. However, the strategic imperative seems undeniable. In an increasingly unpredictable world, securing the supply of essential medicines has moved from a ‘nice-to-have’ to a national priority. And where national priorities go, investment often follows.
View the full Basket:U.S. Drug Manufacturing | Multi-Billion Investment Push
View the full Basket:U.S. Drug Manufacturing | Multi-Billion Investment Push
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article